Publications by authors named "E Chio"
Objective: Nasal surgery can improve patient-reported obstructive sleep apnea (OSA) outcomes as well as adherence with medical device treatments. The aim of this study was to examine whether previous nasal surgery was associated with hypoglossal nerve stimulation (HNS) therapy outcomes.
Study Design: Retrospective observational cohort study was performed utilizing the multicenter international HNS registry (ADHERE).
Hypoglossal Nerve Stimulator Lead Extrusion Into the Pharynx.
Otolaryngol Head Neck Surg
January 2025
Article Synopsis
- Passive administration of the monoclonal antibody cocktail CAS + IMD showed positive clinical outcomes in hospitalized COVID-19 patients, particularly those who were seronegative at the start of treatment.
- The study involved 46 patients and used advanced immunoprofiling techniques to assess how the antibody treatment influenced immune responses over time, from October 2020 to April 2021.
- Results indicated that CAS + IMD not only reduced acute inflammation but also enhanced recovery without harming the host's T cell immune response, suggesting a beneficial anti-inflammatory effect that needs further exploration.
Device-related outcomes following hypoglossal nerve stimulator implantation.
J Clin Sleep Med
September 2024
Study Objectives: Hypoglossal nerve stimulation (HGNS) has been widely used to treat obstructive sleep apnea in selected patients. Here we evaluate rates of revision and explant related to HGNS implantation and assess types of adverse events contributing to revision and explant.
Methods: Postmarket surveillance data for HGNS implanted between January 1, 2018 and March 31, 2022, were collected.
Background: Nasal epithelial cells are important regulators of barrier function and immune signaling; however, in allergic rhinitis (AR) these functions can be disrupted by inflammatory mediators. We aimed to better discern AR disease mechanisms using transcriptome data from nasal brushing samples from individuals with and without AR.
Methods: Data were drawn from a feasibility study of individuals with and without AR to Timothy grass and from a clinical trial evaluating 16 weeks of treatment with the following: dupilumab, a monoclonal antibody that binds interleukin (IL)-4Rα and inhibits type 2 inflammation by blocking signaling of both IL-4/IL-13; subcutaneous immunotherapy with Timothy grass (SCIT), which inhibits allergic responses through pleiotropic effects; SCIT + dupilumab; or placebo.